PT-31, a putative α2-adrenoceptor agonist, is effective in schizophrenia cognitive symptoms in mice-Reference-Cited by-同舟云学术

PT-31, a putative α2-adrenoceptor agonist, is effective in schizophrenia cognitive symptoms in mice

Published:2019-10 Issue:7 Volume:30 Page:574-587
ISSN:0955-8810
Container-title:Behavioural Pharmacology
language:en
Short-container-title:

Author:

Betti Andresa Heemann,Antonio Camila Boque,Herzfeldt Vivian,Pitta Marina Galdino da Rocha,da Rocha Pitta Ivan,do Rego Jean-Luc,do Rego Jean-Claude,Vaudry David,Rates Stela Maris Kuze

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Psychiatry and Mental health,Pharmacology

Reference78 articles.

1. Mechanisms of action of ketamine.;Adams;Anaesthesiol Reanim,1998

2. Pharmacological stimulation of locus coeruleus reveals a new antipsychotic-responsive pathway for deficient sensorimotor gating.;Alsene;Neuropsychopharmacology,2011

3. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions.;Arnsten;Biol Psychiatry,2005

4. The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.;Arnsten;Expert Rev Neurother,2010

5. Catecholamine influences on dorsolateral prefrontal cortical networks.;Arnsten;Biol Psychiatry,2011

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antidepressant effect of PT-31, an α₂-adrenoceptor agonist, on lipopolysaccharide-induced depressive-like behavior in mice;Behavioural Pharmacology;2024-07-19

2. Development and pharmacological evaluation of liposomes and nanocapsules containing paroxetine hydrochloride;International Journal of Pharmaceutics;2024-07

3. Specific biomarkers and neurons distribution of different brain regions in largemouth bass (Micropterus salmoides);Frontiers in Endocrinology;2024-04-30

4. New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists;Neuropsychiatric Disease and Treatment;2024-03

5. Genotoxic and Mutagenic Assessment of PT-31, a Molecule with Antipsychotic Potential;Drug Delivery Letters;2023-12